http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2007529518-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-36 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-4846 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-43 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-36 |
| filingDate | 2005-02-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2007-10-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-2007529518-A |
| titleOfInvention | Factor IXA for the treatment of bleeding disorders |
| abstract | The present invention provides a method of treating a bleeding disorder in a subject by administration of a factor IXa enriched preparation, the method comprising at least 10% factor IXa (mg / mg total protein). Administering a pharmaceutical preparation. Factor IXa can be produced by proteolytically activating factor IX produced by recombinant techniques. The present invention also provides a method for producing Factor IXa from the plasma fraction, which results in a Factor IXa product that contains little or no precalcylenic activity. |
| priorityDate | 2004-03-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 90.